Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0745 • ACR Convergence 2021
Patient-reported Outcomes and Safety Measures in Patients with Rheumatic Diseases Who Switched from Reference or Other Biosimilar Etanercept to Biosimilar Etanercept GP2015 and in Biologic-naïve Patients Starting a Treatment with GP2015: 12-month Interim Analysis from a Real-world Study
Ayman Askari¹, Marc Schmalzing², Slawomir Jeka³, Javier De Toro Santos⁴, Eduardo Collantes-Estevez⁵, Fabricio Furlan⁶, Sohaib Hachaichi⁶ and Herbert Kellner⁷, ¹The Robert Jones and Agnes Hunt Orthopaedic Hospital, Shropshire, United Kingdom, ²Rheumatology/Clinical Immunology, Department of Internal Medicine II, University of Wuerzburg, Wuerzburg, Germany, ³Clinic and Department of Rheumatology and Connective Tissue Diseases, University Hospital No 2 in Bydgoszcz Collegium Medicum UMK in Toruń, Bydgoszcz, Poland, ⁴University Hospital Coruña, Servicio de Reumatología, A Coruña, Galicia, Spain, ⁵IMIBIC/Reina Sofia Hospital/University of Córdoba, Córdoba, Spain, ⁶Hexal AG (A Sandoz company), Holzkirchen, Germany, Holzkirchen, Germany, ⁷Hospital Neuwittelsbach, Center for Rheumatology and Gastroenterology, Munich, Germany, Munich, Germany
Background/Purpose: GP2015 is a biosimilar of etanercept (ETN). COMPACT is an ongoing, non-interventional study, evaluating the effectiveness, safety, and quality of life with GP2015 treatment…
Abstract Number: 0797 • ACR Convergence 2021
Psychosocial Wellbeing and Illness Perceptions During the Early Disease Phase Predict Sustained Remission in Rheumatoid Arthritis
Michal Doumen¹, Diederik De Cock¹, Sofia Pazmino¹, Delphine Bertrand¹, Rene Westhovens² and Patrick Verschueren³, ¹KU Leuven, Leuven, Belgium, ²University Hospitals KU Leuven, Maaseik, Belgium, ³University Hospitals Leuven - KULeuven, Leuven, Belgium
Background/Purpose: Patient-reported outcomes (PROs) relating to global psychosocial wellbeing are rarely assessed in clinical trials for rheumatoid arthritis (RA), and specifically not to tailor additional…
Abstract Number: 0815 • ACR Convergence 2021
Implementing Treat to Target (TTT) for Rheumatoid Arthritis (RA) Through a Virtual Learning Collaborative (LC) Program During COVID
DH Solomon¹, Theodore Pincus², Nancy Shadick¹, Jacklyn Stratton¹, Jack Ellrodt¹, Leah Santacroce¹, Jeffrey Katz¹, Josef Smolen³, Prem Chatpar⁴, Breanna Mundell⁴, Mary Stocks⁴, Christina Downey⁵, Karina Torralba⁶, Douglas White⁷, Meggan Baudek⁷, Steven Szlembarski⁷, Sharon Barnhart⁷, Jawad Bilal⁸, Dylan Lee⁸, Albert Redford⁸, Julia Buchfuhrer⁹, Helene Kramer⁸, C. Kent Kwoh¹⁰, Michel Villatoro-Villar⁸, Asha Patnaik¹¹, Edgardo Guzman¹¹, Rebecca Trachtman¹², John Tesser¹³, Dijana Music¹⁴, Lexi Mickey¹⁵, Mona Amin¹⁶, Jeffrey Potter¹⁷, Juan Schmukler¹⁸, Joshua Sundhar¹⁹, Jessica Sheingold²⁰, Diane Horowitz²¹, Hannah Gulko²¹, Robert Quinet²², Swathi Dhulipala²³, Ronak Patel²⁴, Chandana Keshavamurthy²⁵, Guiset Carvajal Bedoya²⁶, Rhonda Dunn²⁷, Bharat Kumar²⁷, Aleksander Lenert²⁷, Hanna Zembrzuska²⁷ Matthew Gebre²⁸, Petar Lenert²⁹, Allen Anandarjah³⁰, Annie Yang³⁰, Linda Grinnell-Merrick³⁰, Shadefai Goldsmith³⁰, Jonna Zelie³⁰, Leanna Wise³¹, Nicole Zagelbaum Ward³² and Jeffrey Kaine³³ ¹Brigham and Women's Hospital, Boston, MA, ²Rush University Medical Center, Chicago, IL, ³University of Vienna, Vienna, Austria, ⁴Dr. Chatpar and Associates, LLC, Plainview, NY, ⁵Loma Linda University Medical Center, Redlands, CA, ⁶Division of Rheumatology, Department of Medicine, Loma Linda University Healthcare, Loma Linda, CA, ⁷Gundersen Health, La Crosse, WI, ⁸University of Arizona, Phoenix, AZ, ⁹University of Arizona, Pheonix, AZ, ¹⁰University of Arizona College of Medicine, Tuscon, AZ, ¹¹Stony Brook School of Medicine, Stony Brook, NY, ¹²Icahn School of Medicine at Mount Sinai, New York, NY, ¹³Arizona Arthritis & Rheumatology Associates, P.C., Phoenix, AZ, ¹⁴Arizona Arthritis and Rheumatology Associates, Glendale, AZ, ¹⁵Arthritis and Rheumatology Associates- Glendale, Glendale, AZ, ¹⁶Arthritis and Rheumatology Associates- Phoenix, Phoenix, AZ, ¹⁷Arthritis & Rheumatism Associates, Wheaton, MD, ¹⁸Mount Sinai- Chicago, Chicago, IL, ¹⁹Arthritis Rheum & Back Disease Assoc., Voorhees, NJ, ²⁰MedStar Georgetown University Hospital, Washington, DC, ²¹Northwell Health, Great Neck, NY, ²²Ochsner Health, River Ridge, LA, ²³Ochsner Clinic Foundation, River Ridge, LA, ²⁴Ochsner Health, Jefferson, LA, ²⁵Ochsner, New Orleans, LA, ²⁶University of Colorado, Aurora, CO, ²⁷University of Iowa, Iowa City, IA, ²⁸Loma Linda University Medical Center, Loma Linda, CA, ²⁹University of Iowa Medical School, Iowa City, IA, ³⁰University of Rochester, Rochester, NY, ³¹LAC+USC/Keck Medicine of USC, Pasadena, CA, ³²LAC+USC Medical Center, Los Angeles, CA, ³³Cullowhee, NC
Background/Purpose: TTT has been shown in multiple RCTs to be an effective paradigm for managing RA, however TTT has not been uniformly implemented in US…
Abstract Number: 0832 • ACR Convergence 2021
Consistency in Time to Response with Upadacitinib as Monotherapy or Combination Therapy and Across Patient Populations with Rheumatoid Arthritis
Andrea Rubbert-Roth¹, Bernard Combe², Zoltan Szekanecz³, Stephen Hall⁴, Boulos Haraoui⁵, Suzan Mansour Hussein Attar⁶, Anna-Karin Ekwall⁷, Yanna Song⁸, Tim Shaw⁹, Orsolya Nagy⁸ and Ricardo Xavier¹⁰, ¹Kantonspital St Gallen, St.Gallen, Switzerland, ²CHU Montpellier Montpellier University, Montpellier, France, ³Division of Rheumatology, University of Debrecen, Faculty of Medicine, Debrecen, Hungary, ⁴Emeritus Research and Monash University, Melbourne, Australia, Melbourne, Australia, ⁵Institut de Rhumatologie de Montréal, Montréal, QC, Canada, ⁶King Abdulaziz University, Jeddah, Saudi Arabia, Jeddah, Saudi Arabia, ⁷University of Gothenburg, Gothenburg, Sweden, ⁸AbbVie Inc., North Chicago, IL, ⁹AbbVie Inc., North Chicago, ¹⁰Departamento de Reumatologia, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
Background/Purpose: Upadacitinib (UPA) has demonstrated efficacy in patients with moderate-to-severe rheumatoid arthritis (RA) across various patient populations.1–4 This post hoc analysis aimed to evaluate the…
Abstract Number: 0958 • ACR Convergence 2021
Risk Factors for Major Adverse Cardiovascular Events in Patients Aged ≥ 50 Years with RA and ≥ 1 Additional Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors
Christina Charles-Schoeman¹, Maya Buch², Maxime Dougados³, Deepak L Bhatt⁴, Jon Giles⁵, Ivana Vranic⁶, Joseph Wu⁷, Cunshan Wang⁷, Sujatha Menon⁷, Jose L Rivas⁸, Arne Yndestad⁹, Carol A Connell⁷ and Zoltan Szekanecz¹⁰, ¹Department of Medicine, University of California, Los Angeles, Los Angeles, CA, ²University of Leeds, Leeds, United Kingdom, ³Université de Paris . Department of Rheumatology - Hôpital Cochin. Assistance Publique - Hôpitaux de Paris . INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité. Paris, France., Paris, France, ⁴Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ⁵Columbia University, New York, NY, ⁶Pfizer Inc, Tadworth, Surrey, United Kingdom, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer SLU, Madrid, Spain, ⁹Pfizer Inc, Oslo, Norway, ¹⁰Division of Rheumatology, University of Debrecen, Faculty of Medicine, Debrecen, Hungary
Background/Purpose: To identify independent risk factors for major adverse cardiovascular (CV) events (MACE) in ORAL Surveillance (NCT02092467), a long-term, randomized, open-label, non-inferiority, Phase 3b/4 safety…
Abstract Number: 1017 • ACR Convergence 2021
Osteoclast-Specific Transmembrane Protein (OC-STAMP) Regulates Osteoclastogenesis and Inhibits Inflammation in an Acute Arthritis Model
Maria de la Luz Garcia-Hernandez¹, Javier Rangel-Moreno¹, Ananta Paine¹, Jacob R. Jones¹, Marc Nuzzo¹, Lidsay N. Schnur² and Christopher Ritchlin¹, ¹Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, ²University of Rochester, Rochester, NY
Background/Purpose: Dendritic Cell (DC)-Specific Transmembrane Protein (STAMP) expressed by osteoclast precursors is required for cell-cell fusion in the formation of the osteoclast (OC) polykaryon. Genetic…
Abstract Number: 1149 • ACR Convergence 2021
Efficacy of Alendronate for Prevention of New Fractures and Vertebral Deformities in Patients with Rheumatologic Disorders on Chronic Glucocorticoid Therapy: A Systematic Review and Meta-analysis
Saffa Iftikhar¹, Waleed Khokher², Ashu Acharya¹, Joan Gekonde³, Nithin Kesireddy², Rawish Fatima¹ and Nezam Altorok², ¹University of Toledo Medical Center, Toledo, OH, ²University of Toledo, Toledo, OH, ³University of Toledo, Sylvania Township, OH
Background/Purpose: Glucocorticoids are commonly used in patients with rheumatologic conditions including but not limited to Rheumatoid Arthritis, Polymyalgia Rheumatica, Systemic Lupus Erythematous and so on.…
Abstract Number: 1208 • ACR Convergence 2021
Composite Articular Index Including Acute Phase Reactants Should Not Be Used in Patients with Rheumatoid Arthritis Treated with Il6 Inhibitors but May Be Useful in Those Receiving Jak Inhibitors: Ultrasound Evidence
Andrés Ponce¹, Beatriz Frade-Sosa², Ramirez Julio³, Núria Sapena¹, Roberto Gumucio², Virginia Ruiz-Esquide², Rosa Morlà², Marta Bassas², Juan D Cañete⁴ and Jose A Gomez-Puerta², ¹Rheumatology Department, Hospital Clínic, Barcelona, Spain, ²Hospital Clínic de Barcelona, Barcelona, Spain, ³Hospital Universitari Clinic, Barcelona, Spain, ⁴Rheumatology Department, Hospital Clinic, Barcelona, Spain
Background/Purpose: IL6 inhibitors (IL6i) have a dramatic effect on the reduction of C reactive protein (CRP) that does not always correlate with a significant improvement…
Abstract Number: 1224 • ACR Convergence 2021
Low CD39 Expression on B Cells Predicts the Occurrence of Anti-Drug Antibodies in RA Patients Treated with Rituximab
Samuel Bitoun¹, Bineta Ly², Signe Hässler³, Audrey Paoletti⁴, Aude Gleizes⁵, Salima Hacein-Bey⁵, Philippe Bröet³, Marc Pallardy⁶ and Xavier Mariette⁷, ¹Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, Université Paris-Saclay, INSERM UMR 1184 FHU CARE, Paris, France, ²INSERM U1184, Université Paris Saclay, Le Kremlin Bicêtre, France, ³CESP, INSERM UMR 1018, Universite Paris-Saclay, Villejuif, France, ⁴INSERM U1184, Université Paris Saclay, le kremlin bicetre, France, ⁵Hôpital Bicètre, APHP, Université Paris-Saclay, Le Kremlin Bicêtre, France, ⁶Faculté de Pharmacie, Université Paris-Saclay, Chatenay Mallabry, France, ⁷Université Paris- Saclay, Rheumatology, Paris, France
Background/Purpose: Anti-Drug antibodies (ADAb) are well studied and have an impact on response to treatment with monoclonal anti-TNF biologics. Rituximab treatment has an important immunogenic…
Abstract Number: 1240 • ACR Convergence 2021
Biomarker Driven Dissection of Inflammation Modulatory Effects of Upadacitinib versus Abatacept in Patients with Active Rheumatoid Arthritis Refractory to Biologic DMARDs
Fang Cai¹, Thierry Sornasse², Feng Hong³, Heidi Camp⁴, Koji Kato⁵ and Iain McInnes⁶, ¹AbbVie, Redwood City, CA, ²AbbVie Inc, Redwood City, CA, ³AbbVie, Worcester, MA, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie Inc, Shinagawa- Ku, Japan, ⁶University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom
Background/Purpose: In patients with active rheumatoid arthritis (RA) refractory to biologic DMARDs (bDMARD-IR), a phase 3, double-blind and active-controlled study (SELECT-CHOICE) demonstrated that upadacitinib (UPA)…
Abstract Number: 1256 • ACR Convergence 2021
Factors Associated with the Use of Biologic Disease-modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis
Roya Hosseini¹, Souhiela fawaz² and Enrique Seoane-Vazquez², ¹Chapman University School of Pharmacy, Aliso Viejo, CA, ²Chapman University School of Pharmacy, Irvine, CA
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease characterized by polyarthritis of small and large joints. RA is the second most common type…
Abstract Number: 1523 • ACR Convergence 2021
Outcomes and Disease Characteristics in Patients with Rheumatoid Arthritis Treated with Immune Checkpoint Inhibitors for Malignancy at a Single Academic Institution
Megan Hansen, Danny Zakria and Douglas Johnson, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Since the introduction of the first immune checkpoint inhibitor (ICI) in 2011, they have become widely utilized in the treatment of malignancy. It is…
Abstract Number: 1655 • ACR Convergence 2021
Severe Respiratory Infections in Rheumatoid Arthritis Patients with Biologic Therapy: Comparative Study Between Vaccinated and Non Vaccinated Patients
Lucia Cristina Dominguez Casas¹, Paz Rodriguez-Cundin², Trinidad Dierssen³, Miguel Ángel gonzalez-Gay⁴ and Ricardo Blanco⁵, ¹Hospital Universtario San Agustin, Oviedo, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³University of Cantabria, Santander, Spain, ⁴Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁵Hospital Universitario Marqués de Valdecilla, Santadner, Spain
Background/Purpose: Rheumatoid arthritis (RA) patients are at increased risk of severe infections due to the disease itself, and the immunosuppressive treatment. Vaccination programs are designed…
Abstract Number: 1671 • ACR Convergence 2021
COVID-19 in Patients with Rheumatoid Arthritis Compared to Patients with Osteoarthritis During the Pandemic in New York City
Jonah Levine¹, Vivian Bykerk², Lindsay Lally¹, Lisa Mandl¹ and Medha Barbhaiya¹, ¹Hospital for Special Surgery, New York, NY, ²Division of Rheumatology, Hospital for Special Surgery, New York City, NY
Background/Purpose: COVID-19 in patients with rheumatoid arthritis (RA) is poorly understood. A recent study of mostly men with RA demonstrated increased COVID-19 risk in RA…
Abstract Number: 1687 • ACR Convergence 2021
Integrated Laboratory Abnormality Profiles of Upadacitinib with up to 4.5 Years of Exposure in Patients with Rheumatoid Arthritis Treated in a Phase 3 Clinical Trial
Christina Charles-Schoeman¹, Jon Giles², Nancy Lane³, Ernest Choy⁴, Dan Furst⁵, Jiri Vencovsky⁶, Anthony Wilson⁷, Gerd Burmester⁸, Tim Shaw⁹, Yanna Song¹⁰, Heidi Camp¹⁰, Nasser Khan¹⁰, Jillian Yee¹⁰, Samuel Anyanwu¹⁰ and Iain McInnes¹¹, ¹Department of Medicine, University of California, Los Angeles, Los Angeles, CA, ²Columbia University Irving Medical Center, Division of Rheumatology, New York, NY, ³University of California Davis, Hillsborough, CA, ⁴CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom, ⁵University of California Los Angeles, Los Angeles, CA, ⁶Institute of Rheumatology, Prague, Czech Republic, ⁷Center for Arthritis Research, Conway Institute, University College Dublin, Dublin, Ireland, ⁸Charité University Medicine Berlin, Berlin, Germany, ⁹AbbVie Inc., North Chicago, ¹⁰AbbVie Inc., North Chicago, IL, ¹¹University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom
Background/Purpose: Upadacitinib (UPA) is an oral Janus kinase inhibitor approved for the treatment of rheumatoid arthritis (RA). The safety and efficacy of UPA has been…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].